24/7 Market News – (NASDAQ:ENDP) ENDO INTERNATIONAL PLC, shares are moving up nicely this morning more than 9% on 27,000 trades as the company announces to commercialize phase 3 of it’s orthopedic product.
PR Newswire “European Press Releases”
DUBLIN, June 13, 2022 /PRNewswire/ — Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain.
“TLC599 is fully aligned with our commitment to providing differentiated nonsurgical options to healthcare providers and their appropriate patients,” said Patrick Barry, Executive Vice President and President, Global Commercial Operations at Endo. “This investigational product is highly synergistic with our existing orthopedic commercial capabilities and complements our current on-market and in-development orthopedic-focused opportunities.”
“We are thrilled to be partnering with Endo once again,” said George Yeh, President of TLC. “Endo’s proven capabilities in the orthopedic space complement TLC’s expertise in developing novel nanomedicines, and together, we hope to deliver life-enhancing therapies to meet an unmet need with a large patient base.”
Endo currently expects to launch the differentiated branded